Trial
NCT02511041
Immunologic Effects of Supplemental Monosaccharide and Nucleoside Derivatives in Patients With Inherited Disorders of Glycosylation
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
—
Condition
PGM3
Intervention
N-Acetylglucosamine (GlcNAc)
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-07-02